BIOLOGICS (BIOLOGICAL AGENTS): A NEW APPROACH IN THE TREATMENT OF PSORIASIS

Authors

  • Singh Satyapal institute of medical sciences, Banaras Hindu University
  • Tripathi Js
  • Rai Np

Abstract

ABSTRACT
Psoriasis is a chronic inflammatory and multifactorial systemic disorder with predominant manifestation over the skin and/or joints resulting from
interactions between genetic pre-disposition and triggering environmental factors. Due to its systemic nature, patients exhibit a broad spectrum of
symptoms that vary in severity. Although many patients, particularly those with the limited form of the disease, may be treated with topical therapy,
those with extensive (moderate to severe) psoriasis eventually require phototherapy, systemic, or biologic therapy to adequately suppress the systemic,
immunopathogenic process. Biological agents (biologics or biologicals) are a set of different engineered proteins. These are immunosuppressive
agents, designed to selectively interfere with the immune mechanisms that induce psoriasis. Their use is restricted to the treatment of moderate
to severe psoriasis, which has failed to respond to systemic therapies (and/or phototherapy) or where such treatments are contra-indicated or
not tolerated. Biologics are becoming increasingly useful for the treatment of many skin diseases including psoriasis, particularly as alternatives
for patients who have failed to tolerate or respond to conventional systemic therapies or where non-biologic systemic agents are unsuitable due to
the presence of comorbidities. Biological therapies provide a targeted approach to treatment through interaction with specific components of the
underlying immune and inflammatory disease processes.
Keywords: Immunopathogenesis, Biologicals, Psoriasis, Quality of life, Psoriasis area and severity index, Dermatology life quality index.

Downloads

Download data is not yet available.

References

REFERENCES

Menter A, Gottlieb A, Feldman SR, Van Voorhees AS, Leonardi CL,

Gordon KB, et al. Guidelines of care for the management of psoriasis

and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines

of care for the treatment of psoriasis with biologics. J Am Acad

Dermatol 2008;58(5):826-50.

Neimann AL, Porter SB, Gelfand JM. The epidemiology of psoriasis.

Exp Rev Dermatol 2006;1(1):63-75.

Christophers E. Psoriasis – Epidemiology and clinical spectrum. Clin

Exp Dermatol 2001;26(4):314-20.

Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med

;361(5):496-509.

Di Meglio P, Perera GK, Nestle FO. The multitasking organ: Recent

insights into skin immune function. Immunity 2011;35(6):857-69.

Nice Support for Commissioning Psoriasis. 2013. Available

from: https://www.nice.org.uk/guidance/qs40/resources/supportfor-commissioning-for-psoriasis-253668637.

[Last accessed on

Feb 24].

Mustafa AA, Al-Hoqail IA. Biologic systemic therapy for moderate-tosevere

psoriasis: A

review.

J Taibah

Univ Med Sci 2013;8(3):142-50.

Tzu J, Kerdel F. From conventional to cutting edge: The new era of

biologics in treatment of psoriasis. Dermatol Ther 2008;21(2):131-41.

Menter A, Griffiths CE. Current and future management of psoriasis.

Lancet 2007;370(9583):272-84.

Burns T, Breathnach S, Cox N, Griffiths C. Rook’s Textbook of

Dermatology. 8

ed., Vol. 1. Oxford: Wiley-Blackwell; 2010. p. 20-41.

Brown AC, Hairfield M, Richards DG, McMillin DL, Mein EA,

th

Nelson CD. Medical nutrition therapy as a potential complementary

treatment for psoriasis-five case reports. In Altern Med Rev

;9(3):297-307.

Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. Tumor necrosis

factor antagonist mechanisms of action: A comprehensive review.

Pharmacol Ther 2008;117(2):244-79.

Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG,

Gottlieb AB. Efficacy and safety of infliximab monotherapy for plaquetype

psoriasis:

A

randomised trial. Lancet 2001;357(9271):1842-7.

Mehta V, Balachandran C. Biologicals in psoriasis. J Pak Assoc

Dermatol 2008;18:100-09.

Menter A, Tyring SK, Gordon K, Kimball AB, Leonardi CL,

Langley RG, et al. Adalimumab therapy for moderate to severe

psoriasis: A randomized, controlled phase III trial. J Am Acad Dermatol

;58(1):106-15.

da Silva AJ, Brickelmaier M, Majeau GR, Li Z, Su L, Hsu YM, et al.

Alefacept, an immunomodulatory recombinant LFA-3/IgG1 fusion

protein, induces CD16 signaling and CD2/CD16-dependent apoptosis

of CD2(+) cells. J Immunol 2002;168(9):4462-71.

Gottlieb AB, Leonardi CL, Goffe BS, Ortonne JP, van der Kerkhof PC,

Zitnik R, et al. Etanerceptmonotherapy in patients with psoriasis:

A summary of safety, based on an integrated multistudy database. J Am

Acad Dermatol 2006;54 3 Suppl 2:S92-100.

Woolacott N, Bravo VY, Hawkins N, Kainth A, Khadjesari Z, Misso K,

et al. Etanercept and infliximab for the treatment of psoriatic arthritis:

A systematic review and economic evaluation. Health Technol Assess

;10(31):1-239.

Gottlieb AB, Krueger JG, Wittkowski K, Dedrick R, Walicke PA,

Garovoy M. Psoriasis as a model for T-cell-mediated disease:

Immunobiologic and clinical effects of treatment with multiple doses of

efalizumab, an anti-CD11a antibody. Arch Dermatol 2002;138(5):591600.

Koo J, Khera P. Update on the mechanisms and efficacy of biological

therapies for psoriasis. J Dermatol Sci 2005;38(2):75-87.

Boehncke WH, Prinz J, Gottlieb AB. Biologic therapies for psoriasis.

A systematic review. J Rheumatol 2006;33(7):1447-51.

Smith CH, Anstey AV, Barker JN, Burden AD, Chalmers RJ,

Chandler D, et al. British Association of Dermatologists Guidelines

for use of biological interventions in psoriasis 2005. Br J Dermatol

;153(3):486-97.

Reich K, Papp KA, Griffiths CE, Szapary PO, Yeilding N, Wasfi Y,

et al. An update on the long-term safety experience of Ustekinumab:

Results from the psoriasis clinical development program with up to four

years of follow-up. J. Drugs Dermatol 2012;11(3):300-12.

Krueger GG, Langley RG, Leonardi C, Yeilding N, Guzzo C, Wang Y,

et al. A human interleukin-12/23 monoclonal antibody for the treatment

of psoriasis. N Engl J Med 2007;356(6):580-92.

Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM,

Gordon KB, et al. Guidelines of care for the management of psoriasis

and psoriatic arthritis: Section 6. Guidelines of care for the treatment of

psoriasis and psoriatic arthritis: Case-based presentations and evidencebased

conclusions. J

Am

Acad

Dermatol 2011;65(1):137-74.

Smith CH, Anstey AV, Barker JN, Burden AD, Chalmers RJ, Chandler

DA, et al. British Association of Dermatologists’ guidelines for biologic

interventions for psoriasis 2009. Br J Dermatol 2009;161(5):987-1019.

Reich K, Nestle FO, Papp K, Ortonne JP, Evans R, Guzzo C, et al.

Infliximab induction and maintenance therapy for moderate-tosevere

psoriasis:

A

phase III, multicentre,

double-blind trial.

Lancet

;366(9494):1367-74.

Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM,

Gordon KB, et al. Guidelines of care for the management of psoriasis

and psoriatic arthritis: Section 5. Guidelines of care for the treatment

of psoriasis with phototherapy and photochemotherapy. J Am Acad

Dermatol 2010;62(1):114-35.

Published

01-07-2016

How to Cite

Singh Satyapal, T. Js, and R. Np. “BIOLOGICS (BIOLOGICAL AGENTS): A NEW APPROACH IN THE TREATMENT OF PSORIASIS”. Asian Journal of Pharmaceutical and Clinical Research, vol. 9, no. 4, July 2016, pp. 41-43, https://mail.innovareacademics.in/journals/index.php/ajpcr/article/view/12179.

Issue

Section

Review Article(s)